Compare RMBS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | IOVA |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 968.6M |
| IPO Year | 1997 | N/A |
| Metric | RMBS | IOVA |
|---|---|---|
| Price | $92.27 | $2.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $102.00 | $10.45 |
| AVG Volume (30 Days) | 1.4M | ★ 10.2M |
| Earning Date | 02-02-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.64 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $678,488,000.00 | $250,425,000.00 |
| Revenue This Year | $29.01 | $60.94 |
| Revenue Next Year | $16.02 | $60.85 |
| P/E Ratio | $43.12 | ★ N/A |
| Revenue Growth | 31.05 | ★ 175.62 |
| 52 Week Low | $40.12 | $1.64 |
| 52 Week High | $114.55 | $8.15 |
| Indicator | RMBS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 61.10 |
| Support Level | $90.10 | $2.08 |
| Resistance Level | $98.26 | $2.32 |
| Average True Range (ATR) | 5.01 | 0.13 |
| MACD | -0.80 | 0.02 |
| Stochastic Oscillator | 14.38 | 86.54 |
Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.